Faraz Ali
Directeur Général chez TENAYA THERAPEUTICS, INC.
Fortune : 59 920 $ au 30/06/2024
Profil
Mr. Faraz Ali is a Chief Executive Officer, Secretary & Director at Tenaya Therapeutics, Inc. He is on the Board of Directors at Alliance for Regenerative Medicine and Tenaya Therapeutics, Inc. Mr. Ali was previously employed as a Chief Business Officer by REGENXBIO, Inc., a Vice President-Global Commercial Development by bluebird bio, Inc., and a Head-U.S.
Marketing & Strategic Planning by Genzyme Corp.
He received his undergraduate degree from Stanford University and an MBA from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 19 329 ( 0,02% ) | 59 920 $ | 30/06/2024 |
Postes actifs de Faraz Ali
| Sociétés | Poste | Début |
|---|---|---|
| TENAYA THERAPEUTICS, INC. | Directeur Général | 01/06/2018 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Directeur/Membre du Conseil | 01/01/2023 |
Anciens postes connus de Faraz Ali
| Sociétés | Poste | Fin |
|---|---|---|
| REGENXBIO INC. | Corporate Officer/Principal | 05/01/2018 |
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/02/2016 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/11/2010 |
Formation de Faraz Ali
| Harvard Business School | Masters Business Admin |
| Stanford University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| REGENXBIO INC. | Health Technology |
| BLUEBIRD BIO, INC. | Health Technology |
| TENAYA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
